Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€4.66

€4.66

-4.120%
-0.2
-4.120%
-

-

 
18.04.24 / Frankfurt WKN: A14X6S / Name: Champions / Stock / Biotechnology & Medical Research / Small Cap /

Champions Oncology Inc Stock

Champions Oncology Inc took a tumble today and lost -€0.200 (-4.120%).

Pros and Cons of Champions Oncology Inc in the next few years

Pros
?
M***** P*******
?
B****
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Champions Oncology Inc vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Champions Oncology Inc -4.120% 3.097% 0.000% -0.427% -3.320% -50.426% -
Ardelyx Inc. -2.180% -12.086% -15.475% 35.391% 4.706% -16.524% -
Salarius Pharmaceuticals Inc. 1.850% 10.553% -19.266% -71.613% -20.721% -98.176% -99.994%
Evolus Inc -1.830% -7.627% -15.504% 39.744% 16.578% 15.344% -

News

3 Dividend Champions with room for dividend growth: https://www.marketbeat.com/logos/articles/med_20231110113832_3-dividend-champions-with-room-for-dividend-growth.jpg
3 Dividend Champions with room for dividend growth

The World Series champion Texas Rangers recently paid nice dividends for sports bettors. For stock investors, there's a different, more predictable group of dividend payers worth betting on — the

Champions Oncology's European Research Operations Site Receives ISO-9001:2015 Accreditation and ATS Certification
Champions Oncology's European Research Operations Site Receives ISO-9001:2015 Accreditation and ATS Certification

HACKENSACK, NJ / ACCESSWIRE / November 2, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology